We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma - response to Moreau et al.
- Authors
Leiba, Merav; Avigdor, Abraham
- Abstract
The article discusses reply to the response given by the author relating to the meta-analysis methodology adopted for an induction therapy for multiple myeloma treatment. Topics include reference of meta-analysis in 1904, possible performance of meta-analysis and systematic reviews on diagnostic accuracy and observational studies, and comparison of bortezomibthalidomide-dexamethasone (VTD) and bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy.
- Subjects
META-analysis; MULTIPLE myeloma treatment; SCIENTIFIC observation; BORTEZOMIB; THALIDOMIDE; DEXAMETHASONE; CYCLOPHOSPHAMIDE; HISTORY; THERAPEUTICS
- Publication
British Journal of Haematology, 2015, Vol 168, Issue 4, p604
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.13125